- Conditions
- Migraine Headache
- Interventions
- Propranolol or nadolol, Placebo control, Behavioral Migraine Management (BMM), Optimal Acute Therapy
- Drug · Behavioral
- Lead sponsor
- Ohio University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 2
- States / cities
- Athens, Ohio • Westerville, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetic Gastroparesis
- Interventions
- Metoclopramide Nasal Spray, Placebo Nasal Spray
- Drug
- Lead sponsor
- Evoke Pharma
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 46 more
- Conditions
- Gastroparesis, Diabetic Gastroparesis, Diabetes, Diabetes Mellitus, Delayed Gastric Emptying
- Interventions
- metoclopramide, Placebo
- Drug
- Lead sponsor
- Evoke Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 287 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 65
- States / cities
- Dothan, Alabama • Huntsville, Alabama • Tucson, Arizona + 56 more
- Conditions
- Safety, and Tolerability
- Interventions
- DHE inhalation powder low dose administered via dry powder inhaler (DPI) device, DHE inhalation powder high dose administered via dry powder inhaler (DPI) device, DHE injected intravenously (1 mg), DHE 2 mg administered by nasal spray (Migranal®), Metoclopramide 10mg
- Combination Product · Drug
- Lead sponsor
- Aspeya Switzerland SA
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Diabetic Gastroparesis
- Interventions
- Metoclopramide Nasal Spray, Placebo Nasal Spray
- Drug
- Lead sponsor
- Evoke Pharma
- Industry
- Eligibility
- 18 Years to 75 Years · Male only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Huntsville, Alabama + 45 more